… and does not synergize with sorafenib in an orthotopic HCC in vivo model Despite discouraging
in vitro results, we tested erlotinib ± sorafenib in an orthotopic rat model of HCC, in order …

… sorafenib dose in our cirrhotic rat model with HCC, but due to an important weight loss and
other symptoms, after first days of sorafenib … induction phase like it was done for erlotinib (11). …

… improvement of sorafenib efficacy upon combination with erlotinib in an orthotopic rat model
of … TTP were similar in the sorafenib plus erlotinib and sorafenib plus placebo groups[110]. …

… Taken together, these results show that in spite of the relatively low dose and short treatment
duration used here, the response to sorafenib therapy in this orthotopic HCC rat model was …

… also could be combined with sorafenib to produce additive effects.37 However, when used
in an orthotopic rat model of HCC, erlotinib did not change the tumor cell viability significantly, …

… models are emerging to test new drugs. One solution to the disparity between cancer cell
lines and human tumors is surgical orthotopic … with sorafenib, bevacizumab, erlotinib and …

… %) were similar between the sorafenib plus erlotinib and sorafenib plus placebo groups. …
in a rat model of HCC. Sieghart et al23 found that treatment with erlotinib and sorafenib was not …

… It is used in the treatment of hepatocellular carcinoma and advanced renal cancer[29].
Sunitinib represents another multi-kinase inhibitor and inhibits various receptor tyrosine kinases …

… So far, only the multitargeted tyrosine kinase inhibitor sorafenib has … and orthotopic models
have limitations, these models add … of bevacizumab and erlotinib shows significant biological …

… Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol
2012;57:592… As they point out, hepatocellular carcinoma (HCC) cell lines are largely resistant to …